Archives
-
Ibrexafungerp: Evidence, Context, and Limits
2026-10-07
A source-grounded overview of Ibrexafungerp (MK 3118), emphasizing its rationale for vulvovaginal candidiasis research, preserved in vitro activity at acidic pH, comparison with available evidence categories, and the limitations that prevent laboratory findings from being treated as clinical conclusions.
-
Primary Antibody Dilution Buffer in PCNSL Research
2026-10-06
Explore how Primary Antibody Dilution Buffer can support interpretable IHC, ICC, and ISH studies of PCNSL biology. This article distinguishes assay chemistry from biological evidence and examines what single-cell findings about SLC2A5-mediated fructose metabolism do—and do not—establish.
-
How CAFs Shape PDAC Chemoresistance in 3D Models
2026-10-06
Schuth et al. developed patient-matched three-dimensional pancreatic ductal adenocarcinoma organoid–fibroblast co-cultures to examine how cancer-associated fibroblasts alter treatment response. Their findings connect stromal co-culture with greater organoid proliferation, reduced chemotherapy-induced cell death, inflammatory fibroblast states, and epithelial-to-mesenchymal transition-associated transcriptional changes, while also highlighting the limits of small, in vitro patient-derived models.
-
BIRC2 and BIRC3 Regulation in Pulmonary Epithelium
2026-10-05
Thorne et al. show that inflammatory cytokines and glucocorticoids regulate the related inhibitor-of-apoptosis proteins BIRC2 and BIRC3 in distinctly different ways across pulmonary epithelial models. The study strengthens the view that BIRC3 is a highly inducible, context-dependent response protein, whereas BIRC2 is comparatively constitutive and may support rapid signaling functions.
-
Prochlorperazine: Evidence, Uses, and Limitations
2026-10-05
Prochlorperazine is an established dopamine D2 receptor antagonist used in antiemetic therapy, but its proposed antiviral and anticancer applications remain less certain. This overview compares the available clinical case evidence with supplier-reported laboratory findings and defines the boundaries for melanoma research, cancer research, and related translational claims.
-
Ibrexafungerp: Evidence in Vaginal Candida Research
2026-10-03
A source-grounded overview of Ibrexafungerp, also known as MK 3118, covering its research rationale, low-pH in vitro activity against vaginal Candida isolates, potential applications, evidence comparisons, and the limits of translating laboratory findings into clinical or animal-model conclusions.
-
Doxorubicin Hydrochloride: Applied Research Workflows
2026-10-02
Build more informative cancer and cardiotoxicity experiments with Doxorubicin hydrochloride by pairing viability endpoints with DNA-damage, apoptosis, oxidative-stress, and energy-stress readouts. This workflow also translates the ATF4–CSE–H2S findings from a recent cardiomyopathy preprint into practical assay-design choices.
-
Ciclesonide: Respiratory Research Workflows
2026-10-01
Ciclesonide supports reproducible asthma and allergic rhinitis treatment research by pairing prodrug delivery with rapid intracellular activation to desisobutyryl-ciclesonide. This guide translates that biology into cell-based, airway-inflammation, and cross-disciplinary assay workflows while clearly separating established respiratory evidence from exploratory ERAD applications.
-
DNase I (RNase-free) for Long RNA QC
2026-10-01
DNase I (RNase-free) is more than a cleanup reagent in long-RNA workflows: it is a pre-analytical control for reliable RT-PCR, in vitro transcription, and ddPCR interpretation. This guide connects nuclease mechanism with the quality-assessment strategy used for self-amplifying RNA.
-
β-Elemene: From AMPK Biology to Translational Strategy
2026-09-30
β-Elemene is emerging as a versatile research tool at the intersection of adipocyte biology, apoptosis, inflammation, and neuroprotection. This article examines how AMPK-linked findings in 3T3-L1 cells can inform a disciplined translational strategy while distinguishing evidence-supported mechanisms from hypotheses that still require validation.
-
Etomoxir in Whole-Blood Immunometabolism
2026-09-30
Use Etomoxir to test how fatty acid oxidation shapes cytokine responses in fresh human whole blood, while separating CPT-1 effects from concentration-dependent DGAT activity. This workflow combines standardized stimulation, donor-matched controls, and practical optimization for immunometabolism and metabolic disorder research.
-
Acetylcholine Chloride in Gut–Brain Assays
2026-09-29
Use Acetylcholine Chloride as a defined cholinergic stimulus to separate receptor-level responses from microbiota- and vagus-dependent effects. This workflow translates recent gut–brain findings into practical assay design, concentration planning, controls, and troubleshooting.
-
FTSJ3 Loss, R-Loops, and Lung Cancer Chemosensitivity
2026-09-29
The reference study identifies FTSJ3 as a regulator of R-loop homeostasis and genomic stability in lung cancer cells. Its depletion increases R-loop-associated DNA damage and sensitizes tumors to cisplatin, supporting FTSJ3 as a potential biomarker of chemotherapy response and a therapeutic vulnerability.
-
Z-VAD-FMK: Mechanism, Evidence, and Workflow
2026-09-28
Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor used to test caspase dependence in apoptosis models. Its strongest use is as a mechanistic perturbation, not as proof that all forms of cell death have been prevented.
-
AG-221: From 2-HG Suppression to Causal Biology
2026-09-28
AG-221 (Enasidenib) can reveal more than whether mutant IDH2 activity is inhibited. This article explains how to interpret 2-hydroxyglutarate reduction alongside metabolic adaptation, CD44 biology, and leukemia-cell differentiation in acute myeloid leukemia research.